|
Foundation Medicine, Memorial Sloan-Kettering partner on hematologic cancer test
05-02-2013
EDIT CONNECT
SHARING OPTIONS:
CAMBRIDGE, Mass.
—A partnership was announced today between
cancer diagnostics company Foundation Medicine and the Memorial Sloan-Kettering
Cancer Center for the advancement of patient care in hematologic cancers. The
focus will be the co-development of a new molecular diagnostic
product from
Foundation Medicine that is designed to match patients with hematologic cancers
such as leukemia, lymphoma or myeloma with the best fit in
terms of targeted
therapies or clinical trials for their particular cancer.
"Memorial Sloan-
Kettering is one of the world's premier
cancer centers with deep scientific and clinical understanding of hematologic
cancers and a commitment to
driving a new genomic paradigm of individualized
cancer care," Michael J. Pellini, M.D., president and CEO of Foundation
Medicine, said in a press
release about the partnership. "Our approach is to
collaborate with leaders like Memorial Sloan-Kettering across all areas of
clinical oncology and
cancer genomics and seek partners who are equally committed
to the changing paradigm of cancer care. This is the ideal partnership to
support the
development of our new product for patients with hematologic
malignancies."
The new test is being
developed through the use of RNA
sequencing and DNA sequencing in order to better enable identification of
unique genes and classes of genome
alternations that are linked to hematologic
malignancies. This new test will allow physicians to match genetic alterations
with targeted treatment
plans that may fit each patient's genomic profile.
Technology, methods and computational algorithms
developed
by Foundation Medicine will form the basis of the test, which will be
commercialized by Foundation Medicine in the United States and
internationally,
and Memorial Sloan-Kettering will contribute its clinical and genomic expertise
in hematologic malignancies to accelerate development.
The test is expected to
be commercially available by the end of the year.
"The development of clinical-grade
sequencing is rapidly
changing the practice of oncology, enabling us to more precisely understand and
target the genomic alterations that drive a
patient's individual cancer. We are
partnering with Foundation Medicine to develop a best-in-class assay for
hematologic cancers because we view
achieving this goal as an extension of our
mission as a comprehensive cancer center: making it possible for all patients
to be treated with the therapy
that is matched with their individual cancer,"
Craig B. Thompson, M.D., president and CEO of Memorial Sloan-Kettering Cancer
Center, commented in a
statement.
The new test will complement and be similar to Foundation
Medicine's first product,
FoundationOne, a fully informative genomic profile that
provides identification of a patient's individual molecular alterations for
easier
matching with appropriate therapies and clinical trials. The assay is
geared toward solid tumors and was launched last year.
SOURCE: Foundation Medicine press release Code: E05021301 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|